Quick answer: Small Intestinal Bacterial Overgrowth (SIBO) — the presence of excessive bacteria in the normally near-sterile small intestine — affects an estimated 6–15% of healthy adults and up to 78% of patients with irritable bowel syndrome (IBS), producing bloating, abdominal pain, diarrhea, constipation, malnutrition, and systemic inflammation, yet remains dramatically underdiagnosed because its symptoms overlap with functional GI disorders and standard gastroenterology workup often fails to test for it.
The discovery that most IBS patients have SIBO — not psychosomatic symptoms or “functional” disease without pathophysiology — represents one of functional medicine’s most clinically significant contributions. Pimentel et al. (2000, American Journal of Gastroenterology) first demonstrated that 78% of IBS patients tested positive on lactulose hydrogen breath testing, with antibiotic treatment normalizing breath tests and improving IBS symptoms — transforming IBS from a “functional disorder” into a diagnosable, treatable condition with an identifiable microbial cause. This guide examines SIBO pathophysiology, the three types (hydrogen, methane/IMO, hydrogen sulfide), evidence-based testing and treatment, and the functional medicine approach to relapse prevention.
SIBO Pathophysiology: Why the Small Intestine Should Be (Relatively) Sterile
The healthy small intestine contains fewer than 10^3 bacteria per mL — compared to 10^11–10^12 per mL in the colon. This near-sterility is maintained by four key defenses: (1) Gastric acid — kills swallowed bacteria before they reach the small intestine; hypochlorhydria (from PPIs, H. pylori-induced atrophic gastritis, or aging) is one of the strongest SIBO risk factors; (2) Migrating motor complex (MMC) — the interdigestive “housekeeping wave” that sweeps the small intestine every 90–120 minutes during fasting, propelling residual bacteria toward the colon. MMC dysfunction (from diabetes-related neuropathy, hypothyroidism, opioid use, post-infectious IBS, or eating too frequently) is the single most common cause of SIBO; (3) Ileocecal valve — prevents colonic bacteria from refluxing into the ileum; structural incompetence allows backdoor contamination; (4) Immunoglobulin A — sIgA in the small intestinal lumen restrains bacterial adhesion and overgrowth. When any of these defenses fail, bacteria from the colon colonize the small intestine, fermenting carbohydrates that should reach the large intestine for normal fermentation.
The clinical consequences of SIBO arise from: (1) Premature fermentation of carbohydrates in the small intestine — producing gas (hydrogen, methane, hydrogen sulfide) and the distension that causes bloating; (2) Bacterial bile acid deconjugation — impairing fat absorption and causing fat-soluble vitamin (A, D, E, K) deficiency; (3) Competition with the host for nutrients — vitamin B12 is consumed by bacteria, causing B12 deficiency and neuropathy; (4) Intestinal permeability — bacterial toxins and LPS translocation, triggering systemic inflammation and worsening autoimmune conditions; (5) Systemic effects of absorbed fermentation products — D-lactic acid in rare severe cases, short-chain fatty acid imbalances.
Three Types of SIBO: Hydrogen, IMO, and Hydrogen Sulfide
Hydrogen-dominant SIBO is characterized by elevated breath hydrogen (>20 ppm rise over baseline in 90 minutes on lactulose breath test, or >20 ppm at any time point on glucose breath test) produced by diverse bacterial species (Enterobacteriaceae, Lactobacillus, Bacteroides) fermenting carbohydrates. Clinically associated with diarrhea-predominant IBS (IBS-D) and diarrhea alternating with constipation. Treatment: rifaximin 550mg three times daily for 14 days (Pimentel 2011, NEJM, n=1,260 — rifaximin achieved 40.7% relief of global IBS symptoms vs 31.7% placebo; TARGET-3 trial confirmed durability). Herbals with equivalent efficacy: Herbal FC (allicin/garlic-derived, berberine, neem) — Chedid 2014 found herbal therapy equivalent to rifaximin on breath testing normalization.
Intestinal Methanogen Overgrowth (IMO) — previously called methane-dominant SIBO — is caused not by bacteria but by archaea: Methanobrevibacter smithii, which uses hydrogen produced by other organisms as fuel, producing methane gas. IMO correlates strongly with constipation-predominant IBS (IBS-C): methane gas directly slows intestinal transit (Pimentel 2006, American Journal of Physiology). Treatment: rifaximin PLUS neomycin (or metronidazole) combination — neomycin reduces the hydrogen-producing bacteria that feed methanogens. Atrantil (quebracho, conker tree, peppermint — polyphenol combination) has RCT evidence for methane-dominant SIBO. Lovastatin at low doses is being investigated as anti-methanogen therapy (inhibits isoprenoid pathway of archaea). Hydrogen sulfide SIBO — the most recently characterized type, caused by hydrogen sulfide-producing bacteria (Desulfovibrio, Bilophila wadsworthia); cannot be detected on standard breath tests (requires specialized H2S breath test). Clinically associated with “rotten egg” gas, diarrhea, and low flat-line readings on standard breath tests (“flat line SIBO”). Treatment: bismuth subsalicylate (Pepto-Bismol) to bind H2S, low-sulfur diet to reduce substrate, and specific antibiotics active against sulfate-reducing bacteria.
SIBO Diagnosis: Breath Testing, CDSA, and Clinical Correlation
Lactulose hydrogen/methane breath test (LHBT) is the most widely accessible SIBO diagnostic: the patient drinks a lactulose solution (10g) after a 12-hour prep fast, then breathes into tubes at 20-minute intervals for 3 hours. Lactulose is not absorbed — it travels the entire GI tract, producing early (within 90 minutes) hydrogen/methane peaks if bacteria are in the small intestine, later peaks from normal colonic fermentation. Glucose hydrogen breath test (GHBT) is more sensitive for proximal SIBO (jejunum) — glucose is absorbed in the proximal small intestine, so any early hydrogen rise is definitively from proximal overgrowth — but misses distal ileal SIBO. Tri-gas breath test (measuring H2, CH4, and H2S simultaneously) is the most comprehensive and is now offered by several reference labs (QuinTron, Commonwealth Diagnostics International).
Small bowel aspirate and culture (>10^3 CFU/mL from jejunum) is the historical gold standard — but requires upper endoscopy, measures only a single time point, and aerobic culture misses the anaerobes that are often predominant in SIBO. Comprehensive stool testing (GI-MAP, Genova GI Effects) is complementary — assessing overall microbiome composition, pathobionts, digestive markers, and intestinal permeability — but does not diagnose SIBO directly, as it measures colonic flora. SIBO can be confirmed or suspected from elevated fecal calprotectin (SIBO-associated intestinal inflammation), elevated organic acids (D-arabinitol from Candida, indican from bacterial protein fermentation), and serum antibodies to cytolethal distending toxin B (CdtB) and vinculin (anti-vinculin antibody — IBS-Smart test) — identifying post-infectious IBS/SIBO caused by food poisoning (Campylobacter, Salmonella, E. coli O157) that damaged the interstitial cells of Cajal driving MMC dysfunction.
The Elemental Diet: The Nuclear Option for Severe SIBO
The elemental diet — a pre-digested formula containing amino acids (not proteins), glucose oligomers, and medium-chain triglycerides — is absorbed entirely in the proximal small intestine, providing no substrate for bacterial fermentation. Pimentel et al. (2004, Digestive Diseases and Sciences) found 2-week elemental diet normalized breath tests in 80% of SIBO patients — equivalent or superior to antibiotic therapy for many cases. The mechanism is essentially “starvation” of the overgrown bacteria: no fermentable substrate, dramatic reduction in bacterial load within 2 weeks. The elemental diet is particularly useful for: antibiotic-resistant SIBO, severe cases with significant malnutrition, hydrogen sulfide SIBO (where antibiotics are less effective), and bridging to maintenance therapy. It is challenging — 14 days of liquid-only nutrition — and requires electrolyte monitoring.
The SIBO Relapse Problem: MMC Support and Long-Term Prevention
SIBO relapse rates are notoriously high — 40–44% within 9 months in studies of rifaximin-treated patients (Lauritano 2008). This reflects an important truth: antibiotics treat the overgrowth but not the underlying cause. Functional medicine’s relapse prevention strategy addresses the root causes:
MMC support: Low-dose naltrexone 1.5–4.5mg (stimulates MMC through opioid receptor modulation — distinct from LDN’s anti-inflammatory mechanism; Weinstock 2014 pilot study showed SIBO normalization with LDN); Iberogast (STW5 — prokinetic herbal combination, the most studied prokinetic for MMC stimulation, multiple RCTs for functional dyspepsia); ginger 250–500mg (published prokinetic effects on gastric motility, extends to small bowel); 5-HTP (serotonin precursor — 95% of serotonin is gut-derived; serotonin drives MMC; 5-HTP 100mg at bedtime may enhance overnight MMC sweep); prucalopride (prescription 5-HT4 agonist prokinetic with strong MMC evidence); low-dose erythromycin 50mg (motilin agonist prokinetic, off-label for SIBO prevention). Intermittent fasting: MMC only activates in the fasted state; frequent eating (grazing) chronically suppresses MMC. A 4–5 hour fasting window between meals, and a 12+ hour overnight fast, is essential for MMC function and SIBO prevention. Gastric acid support: Address hypochlorhydria with betaine HCl with meals if indicated (lower abdominal symptoms with betaine HCl may indicate adequate acid; tolerance to 3+ capsules suggests hypochlorhydria); discontinue PPIs when possible (PPI use doubles SIBO risk).
Dietary approaches: Low-FODMAP diet reduces fermentable substrate and symptoms but does NOT treat SIBO — it is a symptom management tool. The Specific Carbohydrate Diet (SCD) and Bi-Phasic Diet (Nirala Jacobi’s SIBO protocol) reduce fermentable carbohydrates more selectively. Elemental formula rotation (partial replacement of meals with elemental formula during stressful periods or symptom flares) provides maintenance benefit. Avoidance of proton pump inhibitors (increase bacterial colonization of small bowel), opioids (dramatically suppress MMC), and frequent small meals (suppress MMC) are behavioral essentials.
Frequently Asked Questions: SIBO and Functional GI
How is SIBO diagnosed?
SIBO is diagnosed primarily through breath testing — lactulose hydrogen/methane/hydrogen sulfide breath test is the most accessible. A rise of ≥20 ppm hydrogen over baseline within 90 minutes, or methane ≥10 ppm at any point, indicates SIBO. Glucose breath test is more sensitive for proximal SIBO. Small bowel aspirate and culture (>10^3 CFU/mL from jejunum) is the historical gold standard but requires endoscopy. The IBS-Smart blood test (anti-CdtB and anti-vinculin antibodies) identifies post-infectious SIBO from prior food poisoning. Comprehensive stool testing (GI-MAP) is complementary — assessing overall microbiome and ruling out other pathogens — but does not directly diagnose SIBO.
What diet is best for SIBO?
No single diet cures SIBO, but several approaches reduce symptoms and fermentable substrate. Low-FODMAP diet (restricting fermentable oligosaccharides, disaccharides, monosaccharides, and polyols — onion, garlic, wheat, certain fruits) reduces bloating and discomfort during treatment but doesn’t address root cause. The Bi-Phasic Diet and Specific Carbohydrate Diet (SCD) are more structured SIBO-specific approaches. Most importantly: maintaining a 4-5 hour fasting window between meals and a 12+ hour overnight fast allows the migrating motor complex (MMC) to sweep the small intestine — the physiological defense against SIBO. Grazing and frequent small meals suppress MMC and promote relapse.
Can SIBO cause weight loss and nutrient deficiencies?
Yes — SIBO can cause significant malabsorption and unintentional weight loss. Small intestinal bacteria deconjugate bile acids (impairing fat absorption and causing steatorrhea), consume vitamin B12 (causing B12 deficiency and neuropathy), compete for iron, and damage the enterocytes responsible for nutrient absorption. Fat-soluble vitamins A, D, E, and K are particularly affected due to bile acid deconjugation. Serum B12, folate, ferritin, zinc, fat-soluble vitamins, and albumin should be assessed and repleted in patients with chronic SIBO. Pancreatic enzyme supplementation with meals may help while the small intestinal lining heals.
What is the connection between SIBO and IBS?
Pimentel et al. (2000) demonstrated that 78% of IBS patients tested positive for SIBO — essentially showing that most IBS is a consequence of small bowel bacterial overgrowth rather than a purely functional condition. Subsequent research confirmed that food poisoning (Campylobacter, Salmonella, E. coli O157) damages the interstitial cells of Cajal controlling the migrating motor complex, creating the MMC dysfunction that allows SIBO to develop. Anti-CdtB and anti-vinculin antibodies (IBS-Smart test) identify this post-infectious mechanism in approximately 36% of IBS patients. Treating SIBO with rifaximin improves IBS symptoms in RCTs, confirming the causal relationship. SIBO is the most treatable and well-evidenced cause of IBS.
SIBO is one of the most common yet underdiagnosed conditions in functional medicine — and one of the most treatable when properly identified and addressed with the full functional medicine toolkit. If you experience chronic bloating, gas, abdominal discomfort, irregular bowel habits, or have been told you have IBS without a clear cause, comprehensive SIBO testing and a targeted treatment protocol may resolve symptoms that have been present for years. Call The Private Practice at (810) 206-1402 to schedule your functional GI evaluation.